Many assay technologies currently exist to develop high-throughput screening assays, and the number of choices continues to increase. Results from a previous study comparing assay technologies in our laboratory do not support the common assumption that the same hits would be found regardless of which assay technology is used. To extend this investigation, a nuclear receptor antagonist assay was developed using 3 assay formats: AlphaScreen, time-resolved fluorescence (TRF), and timeresolved fluorescence resonance energy transfer (TR-FRET). Compounds (~42,000) from the Novartis library were evaluated in all 3 assay formats. A total of 128 compounds were evaluated in dose-response experiments, and 109 compounds were confirmed active from all 3 formats. The AlphaScreen, TRF, and TR-FRET assay technologies identified 104, 23, and 57 active compounds, respectively, with only 18 compounds active in all 3 assay formats. A total of 128 compounds were evaluated in a cell-based functional assay, and 35 compounds demonstrated activity in this cellular assay. Furthermore, 34, 11, and 16 hits that were originally identified in the dose-response experiment by AlphaScreen, TRF, and TR-FRET assay technologies, respectively, were functionally active. The results of the study indicated that AlphaScreen identified the greatest number of functional antagonists. (Journal of Biomolecular Screening 2003:381-392) 
INTRODUCTION
R ecent advances in human molecular genetics have led to an increasing number of potential drug targets, 1 which in turn will place a greater demand on high-throughput screening (HTS) programs to increase productivity. During the past decade, a number of assay technologies, particularly in homogeneous formats, have been developed to facilitate HTS. 1 As a result, many choices now exist in developing specific assays for lead-finding programs. The decision of which technology to use is often based on the cost, speed, quality of the signal, ease of use, and availability of the detection systems. In this decision process, there is a common assumption that the same set of hits will be generated, regardless of which assay technology is used for HTS, and that the choice of which technology to use will have a minimal impact on the number of identified false positives or false negatives. In a previous study, 2 we aimed to address the question of whether similar hits would be identified if a selected library of compounds were evaluated against a biochemical target, using 3 different assay technologies. In that study, the results revealed that, indeed, different hits were identified in fluorescence polarization (FP), time-resolved fluorescence resonance energy transfer (TR-FRET), and scintillation proximity assay (SPA) versions of a tyrosine kinase assay.
The finding that different hits can be identified depending on the assay technology that is used raises important questions concerning the identity of the "true" or relevant hits. For example, does one of the assay technologies identify hits that better correlate with the functional, or secondary, assays in the project team's flowchart than the other assay technologies? Or, alternatively, do all of the assay technologies identify functionally relevant hits, though only different ones? Taken a step further, given the plethora of assay technologies available for developing many biochemical or cellular assays, are there "preferred" assay technologies to use for specific drug targets?
In addition to the increase in the number of drug targets, the size of compound libraries continues to increase as well, creating a further need to increase throughput efficiency. 1 One approach to increasing screening efficiency has been assay miniaturization, using 384-, 1536-, or 3456-well plates, 3 which also reduces assay reagent usage. Another approach to increase assay throughput is to screen a mixture of several compounds, instead of a single compound, per well. Despite the gain in throughput and cost savings, one concern regarding screening compounds in mixtures is whether this approach leads to the generation of more false positives or false negatives.
In an effort to address these questions, we have evaluated a randomly selected library of compounds, either as singles or mixtures of 5 compounds per well, in 3 versions of a farnesoid X receptor (FXR) assay using AlphaScreen, time-resolved fluorescence (TRF), and TR-FRET technologies. Because assays are not usually run in more than one format in a "real-life" HTS program, the results obtained for each format were treated independently of the results in the other formats. Normally, screening hits are selected based on the results from an assay using a single technology and not on what might be expected if other versions of the same assay were run. The hits from these assays were then evaluated in a cellbased functional assay. The study indicates that active compounds identified from different assay formats not only overlapped poorly between assay platforms but also correlated differently with the functional assay results. In addition, compared to singlecompound screening, mixture screening generated a greater number of false-positive and false-negative results.
MATERIALS AND METHODS

Materials
Rat FXR DNA coding for the ligand-binding domain (amino acids 215-469, Genbank U18374) was ligated to plasmid pGEX-4T-3 (Amersham Pharmacia, 27-4583-01, Piscataway, NJ) as a fusion protein with glutathione S-transferase (GST). Expression and purification of the fusion protein FXR-GST were performed as previously described. 4 A biotinylated 25-mer peptide derived from human nuclear receptor coactivator SRC-1 (amino acids 676-700, Genbank U90661) with sequence Biotin-CPSSHSSLTERHKILHRLLQEGSPS was synthesized and purified using standard methods. 5 FXR agonist chenodeoxycholic acid (CDCA), antagonist lithocholic acid (LCA), and all other chemicals were purchased from Sigma (St. Louis, MO). For AlphaScreen, streptavidin-conjugated donor beads and anti-GST antibody-conjugated acceptor beads were purchased from Packard Biosignal (6760603M, Montreal, Canada). For TRF, NeutrAvidin was obtained from Pierce (31000, Rockford, IL), and DELFIA Eu-N1-labeled anti-GST antibody was purchased from PerkinElmer (AD0043, Boston, MA). For TR-FRET, LANCE Eu-W1024labeled anti-GST antibody was also purchased from PerkinElmer (AD0065), and APC-labeled streptavidin was obtained from Prozyme (PJ25S, San Leandro, CA).
Screening procedure
In this study, a total of 42,240 compounds from Novartis synthetic compound library were randomly selected. They were evaluated, in parallel, as single compounds and as pools of 5 arbitrarily mixed compounds in the primary screen with the 3 different assay formats. The concentration of each compound in the assays, either in single or in mixtures, was approximately 10 µM. Test compounds were transferred to assay plates using the Quadra 384 pipettor (Tomtec, Hamden, CT). All other assay reagents were added using a Multidrop 384 reagent dispenser (Titertek, Huntsville, AL). After primary screening, a deconvolution experiment was carried out to identify the active compound in the mixtures, whereby each of the 5 compounds in the active mixtures was evaluated individually at a concentration of approximately 10 µM. In addition, all active compounds identified in the singlecompound screening procedure were selected and evaluated again in a confirmation assay. Both the deconvolution and confirmation experiments were carried out in duplicate, and the average of the duplicate experiments was calculated for data analysis. Subsequently, fresh powders of all the confirmed positive compounds from either single-compound screening or mixture screening were obtained and dissolved into 100% DMSO. Serial dilution was then performed to carry out 11-point dose-response experiments at concentrations from 1 nM to 10 µM in 3 replicate experiments. Serial dilutions for the dose-response experiments were performed using a Tecan Genesis workstation (Tecan, Research Triangle Park, NC). The average result from the replicate experiments was used for data analysis. In the dose-response experiments, 10 µM was the highest concentration of testing compounds. In general, a 4parameter logistical fit, without constraints, was used to obtain the IC 50 values and Hill coefficients. Even though many of the IC 50 values were close to 10 µM, most of those compounds have activities of 60% to 70% inhibition at 10 µM. In general, extrapolation does not introduce a high degree of uncertainty in this situation. All calculations were carried out in ActivityBase, and curve fitting was performed by XLFit.
Assay principle
Bile acids, especially CDCA, have been identified as the endogenous ligands for FXR. 5, 6 Once CDCA binds to FXR, it induces a conformational change in the receptor, so that coregulator proteins, such as steroid receptor coactivator 1 (SRC-1), can bind with the receptor. Each of the 3 assay formats was developed as previously described 4 to monitor the compound inhibitory activity on the CDCA-induced interaction between FXR and its coactivator SRC-1. The SRC-1 concentrations were chosen around its Kd values 4 for all 3 assay formats. Reaction with the FXR agonist, CDCA, in the absence of any test compounds represented the positive control, and the reaction in the presence of both the agonist, CDCA, and antagonist, LCA, represented the negative control. All experiments were carried out in a volume of 30 µL/well in 384-well plates.
AlphaScreen assay for FXR
As previously reported by Glickman et al., 4 white, solid 384well plates (Nunc, 264572, Rochester, NY) were used in the AlphaScreen assay. First, 10 µL/well of compound (10 µM; unless specified, concentration within parentheses is final concentration) was incubated with 10 µL/well of a mixture of FXR-GST fusion protein (0.5 nM), biotinylated peptide derived from SRC-1 (5 nM), and AlphaScreen anti-GST antibody-conjugated acceptor bead (10 µg/mL). After incubation for 30 min, 10 µL/well of a second mixture, which consisted of CDCA (50 µM) and AlphaScreen streptavidin-conjugated donor bead (2 µg/mL), was added to start the binding reaction. The plates were read on an AlphaQuest reader (Packard Biosignal) after a 2-h incubation at room temperature. Due to the light sensitivity of AlphaScreen beads, every step of the reagent addition and final reading was carried out under dim light.
TRF assay for FXR
As previously reported, 4 black Maxisorp 384-well plates (Nunc, 460518) were coated overnight at 4°C with 2.5 µg/mL of NeutrAvidin prepared in buffer of 50 mM sodium bicarbonate (pH 9.6), 150 mM NaCl, and 0.2 mg/mL sodium azide. On the next day, the plates were blocked with 10% bovine serum albumin (BSA) for 2 h at room temperature after removal of the coating solution. Subsequently, the plates were washed with cold TBS-Tween (pH 8.0), then individually sealed and stored at -80°C. On the day of the assay, coated plates were removed from the freezer and thawed to room temperature. Then, 10 µL/well of compound was incubated with 10 µL/well of a mixture of FXR-GST (0.5 nM) and biotinylated SRC-1 peptide (100 nM) for 30 min. Subsequently, 10 µL/well of CDCA (50 µM) was added to initiate the interaction of FXR with its coactivator SRC-1. After incubation of the entire binding mixture for 2 h at room temperature, 1 nM of DELFIA Eu-N1 labeled anti-GST antibody (10 µL/well) was added and incubated for 1 h. Plates were aspirated and washed again with cold TBS-Tween (pH 8.0) before 40 µL/well of the enhancement solution was added. Subsequent to vortex and incubation for at least 15 min, the plates were read on a Victor-2 plate reader (PerkinElmer) for the time-resolved fluorescent signal from europium.
TR-FRET assay for FXR
As previously described, 4 10 µL/well of compound was transferred into black 384-well plates (Costar, 3710, Acton, MA). Subsequently, 10 µL/well of a mixture of FXR-GST (0.5 nM), biotinylated SRC-1 peptide (5 nM), streptavidin-XL-APC (2 nM), and europium-labeled anti-GST antibody (1 nM) were added to each well and incubated with the compound. After 30 min, 10 µL/ well of CDCA (50 µM) was added to the reaction mixture. The plates were centrifuged and incubated for 2 h at room temperature and were then read twice on a Victor-2 reader to measure fluorescent signals from both APC and europium. A ratio of APC and europium fluorescence was calculated for the data analysis.
Cell-based reporter gene assay for FXR
DNA encoding amino acids 215 through 469 of rat FXR, the ligand binding domain, was ligated into the pBIND (Promega, E2440, Madison, WI) vector so that it would encode a fusion protein with the DNA-binding domain of Gal4 in the final protein expression plasmid (pBIND-FXR). In a separate plasmid construction (pG5-SEAP), 5 tandem repeats of the Gal4 upstream activation sequence (UAS) were inserted into the pSEAP2-Basic vector (Clontech, 6049-1, Palo Alto, CA), upstream of DNA encoding the secreted alkaline phosphatase (SEAP). A third plasmid pCMVβ (Clontech, 6177-1) was used as a reference plasmid for testing transfection efficiency and compound toxicity to cells. In pCMVβ, DNA encoding for β-galactosidase is under the human cytomegalovirus immediate early (CMV IE) promoter for constitutive expression. Therefore, β-galactosidase activity in cell lysate is proportional to the quantity of healthy cells after transfection, and compound cytotoxicity can be accessed by the loss of βgalactosidase activity. In this study, all compounds that caused greater than 25% loss in β-galactosidase activity in cell lysate were defined as cytotoxic compounds. Three plasmids (pBIND-FXR, pG5-SEAP, and pCMVβ) were cotransfected into HEK293 cells using LIPOFECTAMINE 2000 (Invitrogen, 11668-019, Carlsbad, CA) according to the manufacturer's protocol. In brief, for each well of a 96-well plate, 0.4 µL of LIPOFECTAMINE 2000 reagent was diluted into 25 µL of Opti-MEM I medium (Invitrogen, 31985-062). After 15 min, it was mixed gently with 25 µL of Opti-MEM I medium containing 25 ng pBIND-FXR, 25 ng pG5-SEAP, and 4 ng pCMVβ. Subsequent to a 20-min incubation to allow DNA-LIPOFECTAMINE complexes to form, 50 µL of the mixture was transferred into each well of white, tissue culture-treated, 96-well plates (Costar, 3903) with a Multidrop dispenser (Titertek, Huntsville, AL). In the meantime, HEK293 cells were trypsinized and diluted into 1.2 × 10 6 cells/mL with Dulbecco's modified Eagle's medium (DMEM) plus 5% delipidized fetal bovine serum (FBS). The cell suspension (100 µL) was transferred to each of the wells containing the DNA-LIPOFECTAMINE complexes with a Multidrop dispenser. The plates were incubated at 37°C in a 10% CO 2 incubator for 8 h. Subsequently, 18 µL of each test compound, which were serially diluted, was added to the assay plates to make the final concentration from 10 µM to 1 nM using the PlateMate pipetting station (Matrix, Hudson, NH). In addition, 12 µL of CDCA diluted in DMEM was transferred to each well with the PlateMate dispenser, for a final concentration of 50 µM. The plates
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were then incubated at 37°C in a 10% CO 2 incubator for 24 h. The Phospha-Light chemiluminescent reporter gene assay system (Tropix, BP300, Foster City, CA) was used for the detection of secreted alkaline phosphatase in the cell culture media. From assay plates, 10 µL of cell culture medium was transferred into 96-well black plates (Costar, 3915) by PlateMate. The culture medium was diluted with 30 µL of dilution buffer from the Phospha-Light kit and then heated at 65°C for 30 min to reduce endogenous alkaline phosphatase activity, which is heat sensitive. Subsequently, 40 µL of assay buffer was transferred to each well and incubated for 5 min at room temperature. Next, 40 µL of reaction buffer, which contains alkaline phosphatase substrate CSPD, provided by the Phospha-Light kit, was added to the plate and incubated at room temperature for 20 min before being read for luminescence on a Victor-2 reader. The Gal-Screen chemiluminescent reporter gene assay system (Tropix, GSM1000) was used for the detection of β-galactosidase enzyme activity, following the manufacturer's protocols. In brief, after carefully removing 120 µL of culture medium from each well of the cell plates, 100 µL of reaction buffer containing Gal-Screen substrate was added to cells. The plates were incubated at room temperature for approximately 60 min before measurement for luminescence on a Victor-2 reader.
RESULTS
A randomly selected subset of 42,240 compounds from the Novartis synthetic library were screened in 3 versions of a nuclear receptor FXR antagonist assay, both as singles and as mixtures of 5 compounds per well. The Z′ values 7 of individual testing plates for the 3 assay formats were good, with mean ± SD as 0.78 ± 0.11 (AlphaScreen), 0.72 ± 0.10 (TRF), and 0.88 ± 0.05 (TR-FRET) for single-compound screening and 0.76 ± 0.09 (AlphaScreen), 0.69 ± 0.10 (TRF), and 0.85 ± 0.05 (TR-FRET) for mixture screening. The hit criteria were chosen independently for each of the assay formats after primary mixture screening to limit the hit rate to approximately 0.2% for all 3 technologies. The results of primary screening are summarized in Figure 1 . At a hit criterion of 60% inhibition, 93 mixtures inhibited FXR binding in the AlphaScreen assay format. In contrast to the AlphaScreen format, lower hit rates were obtained for the TRF and TR-FRET versions of the FXR assay. For the TRF assay, 72 active mixtures were identified at a hit criterion of 40% inhibition, whereas 75 active mixtures were identified in the TR-FRET assay at an activity level of 50% inhibition. For the single-compound screening study, the same hit criteria were used as for the mixture screening experiment. As a result, 95 hits were identified in the AlphaScreen assay, which is similar to the number of actives identified in the mixture screen. Interestingly, a greater number of hits (159) were identified in the TRF assay, in comparison to the mixture screen. For the TR-FRET assay, 62 hits were found in the single-compound assay, about 20% fewer than the number of hits from the mixture screen. A comparison of activities between the 3 different assays is shown in the Venn diagrams in Figure 1 . The overlaps in activity were consistent with previous observations, 2 with only 13 single compounds and 11 mixtures showing activity in all 3 assay formats. For mixture screening, a significant number of hits were active in only 1 of the 3 assay formats. For example, 58 out of 93 active mixtures from the AlphaScreen format were not identified in either the TRF or TR-FRET assay formats. Similar results were observed in the single-compound screening, in which 67 of the 95 compounds active in the AlphaScreen assay were not identified in the other 2 assay formats.
Subsequently, a deconvolution experiment was carried out to identify the active compound from all active mixtures in the primary screens. In addition, compounds that were active in the primary single-compound screen were retested in a confirmation experiment. All compounds were evaluated at a concentration of approximately 10 µM. Compounds are normally considered active if they inhibit 50% activity at this concentration, unless the hit limit in the primary assay is lower, in which case the hit limit from the primary screen is used. Therefore, the cutoff level used in the secondary assays was 50% inhibition (AlphaScreen), 40% inhibition (TRF), and 50% inhibition (TR-FRET).
The results from these experiments are summarized in Figure 1 . From deconvolution of the active mixtures, the highest confirmation rate was observed with the AlphaScreen technology, in which 41 compounds (44%) were confirmed active. In contrast, only 11 compounds (15%) were confirmed active in the TRF assay, and 27 compounds (36%) were identified active in the TR-FRET assays. For the single compounds, higher confirmation rates were obtained, in general, in comparison to the mixtures. For example, 78 of 95 compounds (82%) were confirmed active in the AlphaScreen assay, whereas the activities of 43 of 62 compounds (69%) were confirmed in the TR-FRET assay. Similar to the results for the mixtures, the lowest confirmation rate was again found in the TRF assay, in which only 25 of 159 compounds (16%) of the compounds were confirmed active. In addition, it was observed that primary hits with the most potent activities were more likely to be confirmed later compared to the hits just past the cutoff.
As seen in the Venn diagrams ( Fig. 1 ), a similar low degree of overlap occurred in the deconvolution and confirmation experiments, as was observed in the primary screening experiment. For example, only 3 compounds were identified with inhibitory activity in all 3 assays in the deconvolution experiments. Similarly, only 6 compounds were confirmed as active in all assay formats for single-compound screening. Interestingly, most of the compounds active in the AlphaScreen assay (i.e., 56 of the 78 compounds) were not active in either the TR-FRET or TRF formats. Similarly, 26 of the 43 compounds active in the TR-FRET assay were not active in the AlphaScreen or TRF assays.
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An analysis of the deconvolution and confirmation results revealed that single-compound screening identified a greater number of compounds than did mixture screening. These results are summarized in Figure 2A . For the AlphaScreen assay, of the 87 compounds found active in the deconvolution or confirmation assays, 32 compounds were identified in both the mixture and singlecompound screens. However, although an additional 46 active compounds were found in the single-compound screen, only 9 additional compounds were identified in the mixture screen. Similar findings were observed for both the TRF and TR-FRET formats, in which a total of 28 and 49 compounds were identified. Although single-compound screening exclusively identified 17 and 22 compounds in the TRF and TR-FRET assays, respectively, only 3 and 6 exclusive compounds were identified in the mixture screen.
In the next experiment, dose-response curves in all 3 formats were carried out on all compounds (128) found active in either the deconvolution or confirmation experiments. Compounds were considered active if they inhibited > 50% FXR binding at a concentration of 10 µM. The average result from 3 replicate experiments was used for data analysis. As previously reported, 4 the ligand CDCA has very similar affinity to the receptor in all 3 assay formats. In addition, the CDCA concentration was the same in all assays. Therefore, IC 50 values were chosen for comparison instead of calculating K i values using the Cheng-Prusoff adjustment. Of the 128 compounds evaluated in the AlphaScreen assay, 103 compounds (80%) generated IC 50 values ranging from 0.09 to 9.8 µM.
The results for a series of selected compounds with similar and disparate activities between the 3 assays are shown in at http://www.sbsonline.org/publications/toc/Supplementary.pdf. Similar to the results from the primary, deconvolution, and confirmation assays, fewer compounds generated IC 50 values in the TRF and TR-FRET assays. In the former assay, only 23 compounds (18%) generated IC 50 values ranging from 0.29 to 9.1 µM, whereas 56 compounds (44%) in the TR-FRET assay generated IC 50 values ranging from 0.35 to 9.2 µM. Of all the compounds identified, only 18 generated IC 50 values in all 3 assay formats. The greatest degree of overlap occurred between the AlphaScreen and TR-FRET technologies, in which, besides the 18 compounds active in all 3 formats, an additional 33 compounds were active in both formats. In contrast, only 3 additional compounds were active in both AlphaScreen and TRF, and only 1 additional compound was active in both TR-FRET and TRF. Furthermore, 49 compounds were exclusively found by the AlphaScreen assay technology. In contrast, only 1 and 4 compounds were identified exclusively by TRF and TR-FRET assay technologies, respectively.
The data were further analyzed to determine whether compounds that generated IC 50 values were originally identified in the single-compound and/or the mixture primary screens. These results are summarized in Figure 2B . For the AlphaScreen assay, of the 103 compounds that generated IC 50 values, 29 compounds were identified from both the single-compound and mixture screens, 44 compounds were identified from only singlecompound screening, and 7 compounds were identified from only screening mixtures. Furthermore, 23 of the 103 compounds (22%) were detected in neither single-compound screening nor mixture screening, representing false negatives in this study. In the TRF assay, of the 23 compounds that generated IC 50 values, 6 compounds were identified from both the single-compound and mixture screens, 6 compounds were identified from only single-compound screening, and 1 compound was identified from only screening mixtures. As a result, 10 of the 23 compounds (43%) were false negatives, as they were not identified in the TRF primary assay. For the TR-FRET assay, 21 of the 56 compounds were identified from both the single-compound and mixture screens, 17 compounds were identified from only single-compound screening, 5 compounds were identified from only screening mixtures, and 13 (23%) false negatives were identified.
To compare the activities of the active compounds between the assays, we performed several correlations on the IC 50 values obtained in the dose-response experiments. These results are summarized in Figure 3 . A significant correlation was found for the IC 50 values obtained in the AlphaScreen and TR-FRET assays (r = 0.326, p < 0.05) and in the AlphaScreen and TRF assays (r = 0.737, p < 0.001). Although no correlation was obtained when comparing the IC 50 values obtained in the TR-FRET assay with those from the TRF assay (r = 0.432, p > 0.05), this is most likely due to the lower number of compounds that were active in these 2 assays. In reviewing the data in Table 1 , some compounds were observed to possess similar activities in all 3 assays, whereas others revealed somewhat disparate activities. For example, similar IC 50 values were obtained for compound 115 in all 3 assays, whereas appreciably different activities were obtained for compound 71 in the 3 assays. The inhibition curves obtained for representative compounds showing dissimilar (compound 71) and similar (compound 115) activities in the 3 assays are shown in Figure 4 .
One of the questions that arises, at this juncture, is which of the assay technologies identifies functionally relevant hits? Alternatively, does one or more of the assay technologies identify artifacts or false positives that do not demonstrate activity in further assays in the project team's flowchart? To address these questions, we developed a cell-based functional reporter gene assay. The concept of the assay is outlined in Figure 5 . In this assay, CDCA binds to the FXR ligand-binding domain of an FXR/Gal4 fusion protein that binds to the reporter plasmid. This results in a recruitment of nuclear receptor coactivators, such as SRC-1, to interact with FXR and activate gene expression of secreted alkaline phosphatase (SEAP), whose activity is detected as described in the Methods section. The compound's toxicity to the cells was also monitored in the functional assay by detecting β-galactosidase activity in cell lysate. In this experiment, all 128 compounds that were examined in the dose-response experiments were evaluated in the cell-based functional assay. These results are summarized in Figure 6A as a Venn diagram, and a few example dose-response curves are presented in Figure 6B . Of the 128 compounds tested, 35 compounds showed greater than 50% inhibition of CDCA-induced SEAP activity. Of these 35 compounds, 34 were active in at least 1 of the FXR binding assays. Interestingly, 1 of the compounds (89), was inactive in all 3 of the FXR binding assays (i.e., was 1 of the 19 inactive compounds in the dose-response experiment) and appears to be a "true" false negative. Of the set of 34 compounds, all were active in the AlphaScreen assay, and among them, 7 appear to possess cytotoxic activity. In contrast to these results, only 11 and 15 compounds, respectively, were active in the TRF and TR-FRET assays. In addition, 6 of the 11, as well as 5 of the 15, compounds showed activity in the cytotoxicity assay. Furthermore, in reviewing the cross-screen results, only 9 of the 18 compounds that demonstrated inhibitory activity in all 3 FXR binding assays were active in the reporter gene assay.
DISCUSSION
The results from this study demonstrate that different functional hits can be obtained in HTS depending on the assay technology used. These results extend the findings from an earlier study, 2 providing further evidence that there can be significant differences in the hit sets that are generated when different assay technologies are used for the same assay. In addition, the results indicate that screening compounds as singles, rather than mixtures, identified a larger population of hits and produced fewer false-positive and falsenegative compounds.
During the past decade, numerous assay technologies have emerged that provide the lead discovery scientist with various choices when developing a new assay. Results from a previous study provided evidence that different hit sets can be obtained if different assay technologies (SPA, FP, and TR-FRET) are used in an HTS for a tyrosine kinase. Not only were different hit sets obtained, but a low degree of overlap in the hit compounds identified using different assay technologies was observed. The question that remained to be answered, however, was whether the true functional hits could be identified by each of the technologies-that is, did the compounds that did not overlap only represent artifacts, possessing no functional relevance? Or, alternatively, do all of the assay technologies identify functionally relevant hits, albeit different ones? Cell-based assays have been used to functionally characterize screening hits, with the advantage of providing information concerning cell permeability and toxicity, in addition to functional activity. One of the limitations of these types of assays, however, is that true positive compounds in the biochemical assay may appear inactive in the cellular assay due to lack of cell permeability or metabolism of the compound. In this study, all of the hit compounds from the 3 different screens were evaluated in a secondary reporter gene assay. The results of this experiment showed that all 3 assay technologies were able to identify functionally relevant or "true" hits. However, whereas 34 of the 35 compounds found active in the functional assay were identified in the AlphaScreen assay, only a subset of these compounds was active in the TRF or TR-FRET assays. In other words, although screening hits were identified that demonstrated inhibitory activity exclusively in the TRF and TR-FRET assays, no functionally active compounds were identified exclusively by either the TRF or TR-FRET assays. Therefore, for this particular study, the results indicate that the AlphaScreen assay technology had the best capability to detect functional inhibitors of the FXR receptor. The reason for these functional differences, as well as for the low degree of overlap of active compounds between the 3 assays, may be attributable to several factors. One factor that does not appear to contribute is the assay quality, as the Z′ values for all assays ranged from 0.69 to 0.88. However, one possible contributor to the screening results is the difference in the assay conditions of the various screening formats. All 3 assays were developed and optimized independently to best reflect the real HTS situation, where assay conditions are optimized for a particular assay, rather than standardizing conditions for several versions of the same assay. For example, a concentration of 5 nM of the coactivator SRC-1 produced a maximal signal in the AlphaScreen and TR-FRET versions of the FXR assay, but a concentration of 100 nM was required to achieve a good detection window in the TRF assay format. Another difference is that, unlike AlphaScreen and TR-FRET, TRF is a heterogeneous assay that involves several wash steps. In addition to being labor intensive and time-consuming, wash steps can sometimes interfere with the detection of biomolecular interactions, especially for weak binding interactions, and those with rapid dissociation rates. It has been reported that the affinity of the ligand CDCA to the FXR receptor is low, [4] [5] [6] with an EC 50 value of 10 to 50 µM. Such a weak interaction may be disrupted by an assay containing several wash steps, in which the receptor-ligand-coactivator complex may disassemble.
The differences between the AlphaScreen and TR-FRET assay results, though, are more difficult to explain. Although the AlphaScreen technology may be more susceptible to interference by compounds that quench singlet oxygen, this is not supported by the finding that more functional antagonists (34 vs. 15) were identified by the AlphaScreen technology.
In this study, different cutoffs were used for the various screening methods to maintain a hit rate of approximately 0.2% in the primary screen, which was established prior to running the experiments. If the same cutoff point of 40% inhibition had been used for all 3 assays, a larger number of hits would have been identified for both the mixture and single-compound primary screens in the AlphaScreen and TR-FRET assays. From an analysis of the screening data, this would, admittedly, have increased the number of compounds demonstrating overlapping activities between the assays, as well as the number of false positives identified in the AlphaScreen and TR-FRET assays. However, in the normal course of activity in a lead-finding program, the hit rate is not set to be similar across several assays because only 1 assay format is usually evaluated for each screening program. Specifically, if we had only run the AlphaScreen assay, a hit rate of 40% inhibition would never have been selected because this would have resulted in a very high number of hits (> 0.5%). As a result, we selected the cutoff point for each assay format as if that assay were the only assay run in the screening program.
In examining the structures of the hit sets, some interesting observations can be made concerning the chemical structures. Although details of the structures cannot be divulged, it appears that most of the 18 compounds that were active in all 3 assays fall into several chemical series: series A (compounds 26, 28, 29, 43, 44, 45 in Table 1 ), series B (compounds 35, 37), series C (compounds 52, 53, 64, 66), and series D (compounds 101 and 115). For series A, all 6 of the compounds demonstrated functional inhibitory activity. Two additional compounds from this series, 27 and 39, were found to be active in the subset of compounds that were active in the AlphaScreen and TR-FRET assays but not the TRF assay, and these were also found to demonstrate functional activity. Interestingly, no other compounds from series A were present in any of the other hit subsets.
Although compounds in series A appear to show fairly consistent functional activity, this was not the case for either series B or D. For series B, compound 35 was active, but compound 37 was inactive in the functional assay. One other compound from series B was identified in the screening experiments: compound 36 was only active in the TRF assay and was inactive in the cellular assay. For series D, although compounds 101 and 115 were inactive in the functional assay, compounds 118 and 128, which were active in only the AlphaScreen assay, did demonstrate activity in the functional assay (see Table 1 ). No other compounds from series B or D were present in any of the other hit subsets. For series C, none of the compounds demonstrated functional activity, and no other compounds were active in any of the other hit subsets.
Furthermore, in looking at the other subsets, as noted in Figure  6A , none of the compounds that demonstrated activity in only the TRF assay, the TR-FRET assay, or the TRF and TR-FRET assays demonstrated activity in the functional assay. However, there were an additional 17 compounds that were active in the AlphaScreen assay. Most of these compounds fall into additional chemical series from the ones previously mentioned. It would appear, then, that the AlphaScreen technology was able to identify several additional chemical classes, as compared to either TRF or TR-FRET. Although the AlphaScreen technology appears to provide advantages over both the TRF and TR-FRET technologies in this study, further studies will be needed to determine if similar results are observed against additional targets.
An additional question we addressed in this study was whether the differences observed between the 3 assay formats could be attributable to screening mixtures rather than screening single compounds. A common method for increasing the throughput of biomolecular screening is to evaluate pools of several compounds per assay well. In addition to saving time, mixture screening can also reduce the use of costly assay reagents. By evaluating more than 40,000 compounds as both singles and mixtures, we found that the overlap in hits was similarly low for screening single compounds as screening mixtures. The results further showed that mixture screening resulted in not only fewer hits but also more false positives as well as more false negatives being identified compared to single-compound screening (Figure 1 ). For the AlphaScreen assay, 52 of 93 mixtures (56%) did not yield an active compound, whereas only 17 of 95 compounds (18%) were not confirmed active for single-compound screening. Similarly, the false-positive rates for TR-FRET mixture and single-compound screening were 64% and 31%, respectively. In contrast, the false-positive rates for TRF were approximately the same, 85%, which is quite high. The reason for the higher false-positive rate with mixtures may be due to the additive effect produced by each individual compound in the mixture. However, it should be noted that in some mixtures with strong activities, none of the 5 compounds was found to demonstrate any activity when tested individually. For example, 5 compounds that were pooled in a mixture with 87% inhibitory activity in AlphaScreen primary screening showed inhibitory activities of 5%, 1%, -2%, -8%, and -13% when tested separately in the confirmation experiment.
In HTS programs, false negatives are generally of greater concern than false positives because the latter can be eliminated eventually by further validation, whereas false negatives are lost as potential leads. In analyzing the data, one of the questions we asked was how many of the 128 compounds evaluated in the doseresponse experiment were identified in the initial primary screen, as well as in the confirmation (or deconvolution) assays. These results are summarized in Table 2 .
In the AlphaScreen assay, 103 of the 128 compounds evaluated generated IC 50 values. For single-compound screening, 76 of these 103 compounds were identified in the primary screen, and 73 were confirmed active in the confirmation assay. In other words, 27 (26%) and 30 (29%) false negatives occurred in the primary and confirmation assays. For the mixture screening, the numbers were significantly higher, as only 41 of the 103 compounds were identified in the primary screen, and 36 of these were identified in the deconvolution assay. This translates to 62 (60%) and 67 (65%) false negatives for the primary and confirmation assays, respec-tively. Interestingly, a total of 82 of the 103 compounds were identified in either the single-compound or mixture screen, which is similar to the number of compounds identified by the single-compound screen. Comparable results were obtained for the TRF and TR-FRET assays, as shown in Table 2 . These results indicate that mixture screening results in a significantly greater number of false negatives than screening single compounds.
The reason for these findings is most likely due to compound interference in the mixtures. For instance, 1 fluorescent compound can either intensify or quench the fluorescence reading in the TR-FRET assay, which may be able to mask the inhibition activity of the other 4 compounds in the same well. In addition, possible chemical interactions between an active compound with other substances within the same mixture would also lead to false negatives. Whether these disadvantages of screening mixtures outweigh the advantages, in terms of cost savings and increasing screening capacity, will require further evaluation and is beyond the scope of this study.
CONCLUSIONS
The results of this study indicate that different and only partially overlapping sets of functional hits can be obtained from screening programs, depending on the assay technology that is used. Although further work will be required to elucidate the mechanisms that account for these differences (intrinsic variability, technologyspecific interferences, etc.), the question remains how to best address the concern of obtaining different hits with different assay technologies. Currently, it is not clear which assay technology is optimal for specific targets. One possible approach is to consider using replicate determinations in the primary screening process and thus reduce the inherent variability during this part of the screening process. Efforts are currently in progress in our laboratory to address this question. An alternative approach is to consider evaluating compounds in more than 1 assay for a specific target. This approach, which may have been costly just a few years ago, is currently feasible, with today's capabilities of reduced screening times and the ability to reduce costs through miniaturization. Screening 8(4); 2003 www.sbsonline.org 391 ALPHA  103  76  41  82  73  36  80  TRF  23  14  7  15  12  7  13  TR-FRET  56  41  38  50  38  26  43 The numbers of active compounds identified in single-compound and mixture screening are listed. In addition, numbers of the active compounds identified in either of the 2 screening methods are also provided. The difference between those numbers and the final active compounds in the dose-response experiment represents false negatives from screening. ALPHA, AlphaScreen; TRF, time-resolved fluorescence; TR-FRET, time-resolved fluorescence resonance energy transfer.
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